Report
SARTORIUS AG : Sartorius Stedim Biotech# FY review – Recovery ongoing, but takes some time
>Revenues better, order intake below expectations - Q4 revenues of € 850m (-19.9% y-o-y, 1%/3% vs ODDO BHF/consensus) were impacted by a constant currency decline of 17.2%. Sartorius was significantly impacted by the expected inventory reductions and a general reluctance to invest on the part of customers. Order intake of € 835m (-5.8% y-o-y) was -6%/-3% below expectations. We rate the development of the order book as still negative given the lack of visibility for a ...
Underlying
Sartorius AG Pref
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Oliver Metzger
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.